Skip to main content
Premium Trial:

Request an Annual Quote

BioGenex Takes Over Support for Xmatrx Platform Following End of Abbott Partnership

NEW YORK (GenomeWeb News) – BioGenex and Abbott Molecular today announced that BioGenex will take over direct sales and support responsibility for the co-branded Xmatrx instruments, auto FISH reagents, and consumables.

The two firms had a "long and successful collaboration and partnership," said BioGenex, centered on BioGenex's Xmatrx platform, and in 2009 extended an assay deal to market the Xmatrx platform for the automation of Abbott's FISH product line.

Xmatrx FISH, BioGenex said, allows for the walk-away automation of all assay steps necessary to perform Abbott's FISH test, from baking to final cover slip. BioGenex will now support current Xmatrx customers.

Based on individual customer requests, the Fremont, Calif.-based company will also enable the platform to perform other slide-based assays, such as immunohistochemistry, in situ hybridization, and microRNA assays. BioGenex's Xmatrx Elite system comprises a platform for full automation of any slide-based assay, the firm said.

"Abbott and BioGenex are working closely and are committed to ensure seamless transition," BioGenex CEO Krishan Kalra said in a statement. "Hospitals, labs, and research institutions that use Xmatrx can be assured that they will get best in class service and support."

Filed under